Terminated PHASE2 INTERVENTIONAL 2-arm NCT03123588

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Sponsor: Incyte Corporation

Conditions MPN (Myeloproliferative Neoplasms)

Interventions Anagrelide Placebo Ruxolitinib

Updated 23 times since 2017 Last updated: Oct 21, 2021 Started: Nov 14, 2017 Primary completion: Aug 3, 2020 Completion: Aug 3, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrollment issues

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

This PHASE2 trial investigates MPN (Myeloproliferative Neoplasms) and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

23 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2021 — Dec 2021 [monthly]

Terminated PHASE2

Status: Completed → Terminated

▶ Show 18 earlier versions

Jan 2021 — Jun 2021 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Aug 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2019 — Aug 2020 [monthly]

Recruiting PHASE2
Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE2
Jan 2019 — Sep 2019 [monthly]

Recruiting PHASE2
Aug 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Apr 2018 — May 2018 [monthly]

Recruiting PHASE2
Mar 2018 — Apr 2018 [monthly]

Recruiting PHASE2
Jan 2018 — Mar 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE2
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Sep 2017 — Oct 2017 [monthly]

Recruiting PHASE2
Aug 2017 — Sep 2017 [monthly]

Recruiting PHASE2
Jun 2017 — Aug 2017 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2017 — Jun 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Canton, United States , Cary, United States , Danville, United States , Greenville, United States , Lake Charles, United States , Long Beach, United States , Los Angeles, United States , Morristown, United States , Naperville, United States and 15 more locations